sickle cell Archives -

Gene therapies and research into them have grown immensely in recent years, offering more novel tools in regenerative

Commercialization of novel gene-editing technology in beta-thalassemia

https://pharmaphorum.com/partner-content/commercialization-of-novel-gene-editing-technology-in-beta-thalassemia/

Patients with sickle cell disease are facing racism in the NHS that is putting their lives a risk,

Parliamentary probe finds racism evidence in NHS sickle cell care

https://pharmaphorum.com/news/parliamentary-probe-finds-racism-evidence-in-nhs-sickle-cell-care/

The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2

FDA accelerates review of Novartis’ sickle cell drug

https://pharmaphorum.com/news/fda-accelerates-review-of-novartis-sickle-cell-drug/

The FDA has granted Breakthrough Therapy designation to Novartis’ crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in

Novartis’ sickle cell drug gets Breakthrough Therapy designation

https://pharmaphorum.com/news/novartis-sickle-cell-drug-gets-breakthrough-therapy-designation/

Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of

GBT heads to FDA with sickle cell drug voxelotor

https://pharmaphorum.com/news/gbt-heads-to-fda-with-sickle-cell-drug-voxelotor/

Novartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can

Novartis drug cuts serious complications in sickle cell disease

https://pharmaphorum.com/news/novartis-drug-cuts-serious-complications-in-sickle-cell-disease/

Swiss pharma takes option on US biotech.

Novartis buys sickle cell biotech Selexys

https://pharmaphorum.com/news/novartis-buys-us-biotech-selexys/

sickle cell